



Ph. Eur. Monograph 2280: Fexofenadine Hydrochloride Related Substances and Assay

Rajesh Babu Dandamudi, PhD¹, Ronak Singh¹, Heiko Behr, PhD², and Bryan Tackett, PhD³

¹India Phenologix Lab, Phenomenex India, Hitech Defence and Aerospace Park Industrial Area, Mahadeva Kodigehalli, Holbi, Jala Taluka, Bengaluru 562149, India

²Phenomenex Ltd., Deutschland, Zeppelinstr. 5, 63741 Aschaffenburg, Germany

³Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Overview


Fexofenadine Hydrochloride is a selective peripheral H1 blocker and is classified as a second-generation antihistamine used in the treatment of allergy symptoms, such as hay fever and urticaria. This study for Fexofenadine Hydrochloride and its related substances is based on the Ph. Eur. monograph 2280 where a phenylsilyl silica gel stationary phase is used under isocratic conditions. In this application note, we demonstrate the separation of Fexofenadine Hydrochloride from its related substances per the Ph. Eur. monograph using Kinetex™ Biphenyl and Phenyl-Hexyl columns in comparison with the ZORBAX® SB-Phenyl column used in the elucidation of the monograph.

System suitability per Ph. Eur. Monograph 2280 for Fexofenadine Hydrochloride for Related Substances is a minimum resolution of 10 between the peaks due to Fexofenadine Hydrochloride and impurity A. System suitability per Ph. Eur. Monograph 2280 for Fexofenadine Hydrochloride for Assay is a maximum % Relative Standard Deviation (%RSD) of 0.85 for 6 injections and a symmetry factor of the peak for Fexofenadine Hydrochloride of 0.8-1.8. All three columns met the system suitability requirement for resolution between Fexofenadine Hydrochloride and Fexofenadine Impurity A. This demonstrates that the Kinetex Biphenyl and Phenyl-Hexyl columns are suitable alternatives to the ZORBAX SB-Phenyl column for Fexofenadine Hydrochloride related substances.

All the reference solutions were prepared as indicated in Ph. Eur. monograph 2280 for Fexofenadine Hydrochloride. The following certified reference standards (CRS) were purchased from the European Directorate for the Quality of Medicines & HealthCare (EDQM) – Council of Europe; Postal address: 7 Allee Kastner CS 30026 F - 67081 Strasbourg (France):

- Y0000789, Fexofenadine Hydrochloride CRS
- Y0000751, Fexofenadine Impurity A CRS
- Y0000753, Fexofenadine Impurity C CRS

Figure 1. Fexofenadine Hydrochloride Structure.




LC-UV Conditions

- Columns:** Kinetex 5 µm Biphenyl ([00G-4627-E0](#))
Kinetex 5 µm Phenyl-Hexyl ([00G-4603-E0](#))
ZORBAX 5 µm SB-Phenyl
- Dimensions:** 250 x 4.6 mm
- Mobile Phase:** Acetonitrile R / [Buffer](#) / Triethylamine R (350:650:3, v/v/v)
- Buffer:** Dissolve 6.64 g/L of Sodium Dihydrogen Phosphate Monohydrate R and 0.84 g/L of Sodium Perchlorate R in Water for Chromatography R, adjust to pH 2.0 ± 0.1 with Orthophosphoric Acid.
- Flow Rate:** 1.5 mL/min (Isocratic)
- Injection:** 20 µL
- Temperature:** 25 °C
- Detector:** UV @ 220 nm
- System:** Waters® ACQUITY Arc® HPLC


Table 1. Preparation of Test and Reference Solutions

Solution	Composition
Solvent Mixture	Mix equal volumes of Acetonitrile R and Buffer solution.
Test Solution (a)	Dissolve 25.0 mg of <i>Fexofenadine Hydrochloride CRS</i> in 25 mL of the Solvent Mixture .
Test Solution (b)	Dilute 3.0 mL of Test Solution (a) to 50.0 mL with Mobile Phase.
Reference Solution (a)	Same as Test Solution (b).
Reference Solution (b)	Dilute 1.0 mL of Test Solution (a) to 100.0 mL with the Mobile Phase. Dilute 1.0 mL of this solution to 10.0 mL with the Mobile Phase.
Reference Solution (c)	Dissolve 1 mg each of <i>Fexofenadine Impurity A CRS</i> and <i>Fexofenadine Impurity C CRS</i> in 20 mL of Reference Solution (a) and dilute to 200.0 mL with the Mobile Phase.




Figure 2. System Suitability Test for Related Substances Using Reference Solution (c).

Peak No.	Analyte	Retention Time (min)	RRT	Resolution	RRT per Monograph
1	Fexofenadine Hydrochloride	8.29	-	16.70	1.00
2	Fexofenadine Impurity A	13.80	1.66		1.70
3	Fexofenadine Impurity C	27..32	3.30	-	3.20
N = 6 Injections					






Peak No.	Analyte	Retention Time (min)	RRT	Resolution	RRT per Monograph
1	Fexofenadine Hydrochloride	8.14	-	18.19	1.00
2	Fexofenadine Impurity A	13.86	1.70		1.70
3	Fexofenadine Impurity C	30.39	3.73	-	3.20
N = 6 Injections					



Peak No.	Analyte	Retention Time (min)	RRT	Resolution	RRT per Monograph
1	Fexofenadine Hydrochloride	10.72	-	15.62	1.00
2	Fexofenadine Impurity A	18.50	1.72		1.70
3	Fexofenadine Impurity C	34.50	3.22	-	3.20
N = 6 Injections					



Figure 3. System Suitability Test for Assay Using Test Solution (b) / Reference Solution (a).

Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/Chat.

Australia

t: +61 (0)2-9428-6444
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077
cz-info@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

Hong Kong

t: +852 6012 8162
hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Indonesia

t: +62 21 3952 5747
indoinfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Japan

t: +81 (0) 120-149-262
jpinfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: +48 22 51 02 180
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: 800-852-3944 (toll free)
t: 6559 4052 (office main line)
sginfo@phenomenex.com

Slovakia

t: +420 272 017 077
sk-info@phenomenex.com

Spain

t: +34 91-413-8613
esinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287
thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

• All other countries/regions

Corporate Office USA
t: +1 (310) 212-0555
www.phenomenex.com/chat

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

**BE-HAPPY™
GUARANTEE**

Your happiness is our mission. Take
45 days to try our products. If you
are not happy, we'll make it right.
www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/phx-terms-and-conditions-of-sale.

Trademarks

Kinetex and BE-HAPPY are trademarks of Phenomenex. ZORBAX is a registered trademark of Agilent Technologies, Inc. Waters and ACQUITY Arc are registered trademarks of Waters Technology Corporation.

Disclaimer

Comparative separations may not be representative of all applications.

Phenomenex is in no way affiliated with Agilent Technologies, Inc. or Waters Technology Corporation.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2024 Phenomenex, Inc. All rights reserved.



Have questions or want more details on implementing this method? We would love to help!
Visit www.phenomenex.com/Chat to get in touch with one of our Technical Specialists